Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is developing a two-pronged approach to tackle brain disorders that affect millions worldwide. The biopharmaceutical company's pipeline focuses on two significant areas of unmet neurological need: multiple sclerosis (MS) and the acute cognitive and physiological effects of alcohol intoxication.
Multiple sclerosis is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS around the world, with about one million of those in the United States. The disease is most often diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects females at roughly twice the rate of males. Existing treatments for MS often fall short, leaving patients with limited options.
Quantum BioPharma's MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Supporting Lucid-MS's phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital. This collaboration aims to provide deeper insights into the drug's mechanism and efficacy.
In addition to its MS program, the company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. This product addresses a common but often overlooked neurological and physiological issue.
The company's efforts are particularly important given that neurological disorders affect hundreds of millions of people globally. For many patients, existing treatments are inadequate, highlighting the need for innovative therapies like those being developed by Quantum BioPharma.
For more information on the latest news and updates relating to QNTM, visit the company's newsroom at https://ibn.fm/QNTM.
